Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free
  1. Home
  2. Programs
  3. Project Oncology®

Treating High-Risk Biochemically Recurrent Prostate Cancer: An Update from ASCO-GU

ReachMD Healthcare Image
Restart
Resume
Choose a format
Completing the pre-test is required to access this content.
Completing the pre-survey is required to view this content.

Ready to Claim Your Credits?

You have attempts to pass this post-test. Take your time and review carefully before submitting.

Good luck!

Details
Presenters
Comments
  • Overview

    Between 20 and 50 percent of patients with high-risk localized prostate cancer will develop biochemical resistance, but historically, no Level I evidence for treatment was available. That’s why the EMBARK study is the first phase 3 trial to develop Level I evidence looking at monotherapy T suppression versus monotherapy enzalutamide versus combination enzalutamide and leuprolide. Dive into the findings with Dr. Neal Shore, who presented the “Outcomes of Men with High-Risk Biochemically Recurrent Prostate Cancer Who Suspended Enzalutamide Monotherapy Treatment in the Phase 3 EMBARK Study” session at the 2024 ASCO Genitourinary Cancers Symposium. 

Recommended
Details
Presenters
Comments
  • Overview

    Between 20 and 50 percent of patients with high-risk localized prostate cancer will develop biochemical resistance, but historically, no Level I evidence for treatment was available. That’s why the EMBARK study is the first phase 3 trial to develop Level I evidence looking at monotherapy T suppression versus monotherapy enzalutamide versus combination enzalutamide and leuprolide. Dive into the findings with Dr. Neal Shore, who presented the “Outcomes of Men with High-Risk Biochemically Recurrent Prostate Cancer Who Suspended Enzalutamide Monotherapy Treatment in the Phase 3 EMBARK Study” session at the 2024 ASCO Genitourinary Cancers Symposium. 

Schedule14 Dec 2024